Raymond W. Cohen has more than four decades of leadership experience in the life sciences and medical technology industry. From 2014 to 2024, he served as co-founder and Chief Executive Officer of Axonics, Inc., a publicly traded global leader in implantable neuromodulation devices. Under his leadership, Axonics completed its initial public offering in 2018, achieved over $1 billion in revenue within four years of its commercial launch, reached profitability, and was recognized as the fastest-growing technology company in North America, before being acquired by Boston Scientific in November 2024 for $3.7 billion.
In March 2025, as Chairman of SoniVie Ltd., an Israeli clinical-stage renal denervation company, Mr. Cohen led the successful $600 million sale of the company to Boston Scientific. He currently serves on the boards of several public and venture-backed healthcare companies, including Kestra Medical Technologies (Nasdaq: KMTS), InspireMD (Nasdaq: NSPR), and RxSight (Nasdaq: RXST), as well as privately held Nalu Medical (Chairman), Archimedes Vascular (Chairman), Tulavi Medical (Vice Chairman), and Spectrum Vascular (Independent Director). In addition, he is a venture partner with Andera Partners in Paris and Sherpa Capital Partners in Beijing.
